



US005686408A

United States Patent [19]

Moses et al.

[11] **Patent Number:** **5,686,408**[45] **Date of Patent:** **Nov. 11, 1997**[54] **METHOD FOR MODIFYING, DIAGNOSING, AND SCREENING FOR IGF-I SENSITIVE CELL BARRIER PROPERTIES**[75] **Inventors:** Alan C. Moses, Waban; Linda A. Morrow, Newton; Jeffrey S. Flier, West Newton, all of Mass.[73] **Assignee:** The Beth Israel Hospital Association, Boston, Mass.[21] **Appl. No.:** 279,831[22] **Filed:** Jul. 25, 1994**Related U.S. Application Data**[63] **Continuation of Ser. No. 8,461, Jan. 25, 1993, abandoned.**[51] **Int. Cl.⁶** **A61K 38/30**[52] **U.S. Cl.** **514/3; 530/303**[58] **Field of Search** **514/3; 530/303**[56] **References Cited****U.S. PATENT DOCUMENTS**

4,988,675 1/1991 Froesch 514/4

FOREIGN PATENT DOCUMENTS

B2252592 1/1993 Australia .

0331630 6/1989 European Pat. Off. .

0436469A1 7/1991 European Pat. Off. .

9103253 3/1991 WIPO .

WO9325226 12/1993 WIPO .

OTHER PUBLICATIONS

Guler, H.-P. et al. (1988) Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. *Proc. Natl. Acad. Sci. USA*. 85:4889-4893.

Guler, H.-P. (1987) Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. *N. Engl. J. Med.* 317:137-140.

Weinstein, R. et al. (1981) Hormonal requirements for growth of arterial smooth muscle cells in vitro: An Endocrine Approach to Atherosclerosis. *Science* 212:818-820.

Verspohl, E.J. et al. (1984) Dual regulation of glycogen metabolism by insulin and insulin-like growth factors in Human Hepatoma Cells (Hep-G2). *J. Clin. Invest.* 74:1436-1443.

Zenobi, P.D. et al. (1992) Insulin-like growth factor I improves glucose and lipid metabolism in type 2 diabetes mellitus. *J. Clin. Invest.* 90:2234-41.

Smith, P.J. et al. (1988). Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-Li adipocytes. *J. Biol. Chem.* 263:9402-9408.

Wilton, P. et al. (1991). Pharmacokinetic profile of recombinant human insulin-like growth factor I given subcutaneously in normal subjects. *Acta Paediatr. Scand [Suppl]* 377:111-114.

Takano, R. et al. (1991). Repeated sc administration of recombinant human insulin-like growth factor I (IGF-I) to human subjects for 7 days. *Growth Reg.* 1:23-28.

Laron, Z. et al. (1991). Biochemical and hormonal changes induced by one week of administration of rIGF-1 to patients with laron type dwarfism. *Chin. Endocrinol.* 35, 145-150.

Schoenle, E.J., et al., "Recombinant human insulin-like growth factor I (rhIGFI) . . .", *Diabetologia*, pp. 675-679, 1991.

Usala, Anton-Lewis, et al., "Brief Rpt.: Treatment of Insulin-Resistant Diabetic . . .", *NEJM*, vol. 327, No. 12, pp. 853-857, 1992.

Zenobi, Peter, et al., "Effects of IGF-I on Glucose Tolerance . . .", *J. Clin. Invest.*, vol. 89, pp. 1908-1913, Jun. 1992.

Schalch, Don S., et al., "Short-term metabolic effects of rhIGF-I . . .", *Modern Concepts of IGF*, pp. 708-713, 1991.

Elahi, D., et al., "Hemodynamic and Metabolic Responses to Human IGFI . . .", *Modern Concepts of IGF*, pp. 219-224, 1991.

Quin, John et al., "Acute Response to IGF-I in a Patient . . .", *Correspondence Section; NEJM*, vol. 323, No. 20, pp. 1425-1426, 1990.

Primary Examiner—John Ulm*Assistant Examiner*—Karen E. Brown*Attorney, Agent, or Firm*—Lorusso & Loud

[57]

ABSTRACT

A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 µg/kg and less than about 500 µg/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.

10 Claims, 10 Drawing Sheets